Effect of Emepronium Bromide (Cetiprin&amp;reg;) on Symptoms and Urinary Bladder Function after Transurethral Resection of the Prostate

Bonnesen, T; Tikjøb, G; Kamper, Anne-Lise; Am, Nielsen; Jt, Andersen; Sj, Jørgensen

doi:10.1159/000281002

Cited by 7 publications

(3 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several studies have supported that antimuscarinics can depress involuntary bladder contractions (Low 1977, Cardozo and Stanton 1979, Blaivas et al 1980, Naglo et al 1981). On the other hand, there are several reports of insufficient efficacy of antimuscarinics given orally to patients with unstable detrusor contractions (Ritch et al 1977, Walther et al 1982, Bonnesen et al, 1984, Zorzitto et al 1986. It is unclear to what extent this can be attributed to low bioavailability of the drugs used, side effects limiting the dose that can be given, or to atropine resistance.…”

Section: Antimuscarinic (Anticholinergic) Drugsmentioning

confidence: 99%

The pharmacological treatment of urinary incontinence

et al. 1999

View full text Add to dashboard Cite

Section: Antimuscarinic (Anticholinergic) Drugsmentioning

confidence: 99%

The pharmacological treatment of urinary incontinence

et al. 1999

View full text Add to dashboard Cite

“…Therefore it may be that abnormalities in Ca 2+ channel function in the detrusor muscle play an important role in detrusor instability. Consistent with this idea is the fact that anticholinergic drugs, which have been widely prescribed for the treatment of urinary incontinence, have been reported to be only modestly effective (Walter et al 1982;Bonnesen et al 1984;Zorzitto et al 1986). Therefore, drugs with both anticholinergic and Ca 2+ antagonistic activities may be more effective for the treatment of hypercontractility in detrusor smooth muscle than drugs with anticholinergic activity only.…”

Section: Introductionmentioning

confidence: 94%

Inhibitory effects of NS-21, a novel drug for urinary incontinence, and its active metabolite, RCC-36, on L-type calcium currents in isolated guinea pig detrusor smooth muscle cells

Hayashi

Natsukawa

Ukai

et al. 1997

Naunyn-Schmiedeberg's Arch Pharmacol

View full text Add to dashboard Cite

The inhibitory effects of NS-21, a newly developed drug for the treatment of urinary frequency and urinary incontinence, and its active metabolite, RCC-36, on L-type Ca2+ currents (ICa) in guinea pig detrusor smooth muscle cells have been compared to those of terodiline by a whole-cell patch-clamp technique. Like terodiline (10 microM), both NS-21 (10 microM) and RCC-36 (10 microM) induced a sizeable decrease in ICa elicited from a holding potential of -60 mV without changing the current-voltage relationship. The three drugs shifted the inactivation curves for ICa in the hyperpolarizing direction by 13 to 20 mV but had no effect on the activation curves for ICa resulting in a decrease in the calcium window current. The inhibitory effects of NS-21 and RCC-36 were greater than those of terodiline. The three drugs inhibited ICa in a concentration- and holding-potential-dependent manner. The IC50 values at a holding potential of -60 mV were 7.9 microM for NS-21, 6.4 microM for RCC-36, and 5.9 microM for terodiline, and at -40 mV they were 1.3, 1.2, and 3.5 microM, respectively. The ratio calculated by dividing the IC50 value at -60 mV by the value at -40 mV was 6.1, 5.3 and 1.7, respectively, indicating that the inhibitory effects of NS-21 and RCC-36 on ICa were more sensitive to voltage than those of terodiline. These results suggest that NS-21 and RCC-36 could be more effective in the treatment of urinary bladder ailments, such as urinary frequency and urinary incontinence.

show abstract

“…Several studies have supported the theory that antimuscarinics can depress involuntary bladder contractions [22][23][24][25]. On the other hand, there are several reports of insufficient efficacy of antimuscarinics given orally to patients with DO [26][27][28][29]. It is unclear to what extent this can be attributed to the low bioavailability of the drugs used, side effects limiting the dose that can be given, or a resistance phenomenon.…”

Section: Antimuscarinic (Anticholinergic) Drugsmentioning

confidence: 99%

Oxybutynin and its New Transdermal Application for the Treatment of Overactive Bladder

Appell

2006

Womens Health (Lond Engl)

View full text Add to dashboard Cite

It has long been accepted that antimuscarinic agents are the backbone of the pharmacological treatment of overactive bladder. Oxybutynin has been the gold standard of these medications for years due to its efficacy, but suffers from a lack of selectivity for the bladder, and extensive metabolism and lipophilicity result in significant side-effect issues. The transdermal delivery of oxybutynin turns this disadvantage of lipophilicity into an advantage. This, in turn, bypasses gastrointestinal absorption and metabolism by the cytochrome P450 system and reduces the breakdown into metabolites responsible for many of the side effects, while providing equivalent efficacy to the immediate-release oral formulation.

show abstract

Effect of Emepronium Bromide (Cetiprin®) on Symptoms and Urinary Bladder Function after Transurethral Resection of the Prostate

Cited by 7 publications

References 4 publications

The pharmacological treatment of urinary incontinence

The pharmacological treatment of urinary incontinence

Inhibitory effects of NS-21, a novel drug for urinary incontinence, and its active metabolite, RCC-36, on L-type calcium currents in isolated guinea pig detrusor smooth muscle cells

Oxybutynin and its New Transdermal Application for the Treatment of Overactive Bladder

Contact Info

Product

Resources

About